Show simple item record

dc.contributor.authorThompson, Craig P
dc.contributor.authorGrayson, Nicholas E
dc.contributor.authorPaton, Robert S
dc.contributor.authorBolton, Jai S
dc.contributor.authorLourenço, José
dc.contributor.authorPenman, Bridget S
dc.contributor.authorLee, Lian N
dc.contributor.authorOdon, Valerie
dc.contributor.authorMongkolsapaya, Juthathip
dc.contributor.authorChinnakannan, Senthil
dc.contributor.authorDejnirattisai, Wanwisa
dc.contributor.authorEdmans, Matthew
dc.contributor.authorFyfe, Alex
dc.contributor.authorImlach, Carol
dc.contributor.authorKooblall, Kreepa
dc.contributor.authorLim, Nicholas
dc.contributor.authorLiu, Chang
dc.contributor.authorLópez-Camacho, César
dc.contributor.authorMcInally, Carol
dc.contributor.authorMcNaughton, Anna L
dc.contributor.authorRamamurthy, Narayan
dc.contributor.authorRatcliff, Jeremy
dc.contributor.authorSupasa, Piyada
dc.contributor.authorSampson, Oliver
dc.contributor.authorWang, Beibei
dc.contributor.authorMentzer, Alexander J
dc.contributor.authorTurner, Marc
dc.contributor.authorSemple, Malcolm G
dc.contributor.authorBaillie, Kenneth
dc.contributor.authorISARIC4C Investigators
dc.contributor.authorHarvala, Heli
dc.contributor.authorScreaton, Gavin R
dc.contributor.authorTemperton, Nigel
dc.contributor.authorKlenerman, Paul
dc.contributor.authorJarvis, Lisa M
dc.contributor.authorGupta, Sunetra
dc.contributor.authorSimmonds, Peter
dc.date.accessioned2021-01-19T00:31:08Z
dc.date.available2021-01-19T00:31:08Z
dc.date.issued2020-10
dc.identifier.issn1025-496X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/316374
dc.description.abstractBackgroundThe progression and geographical distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United Kingdom (UK) and elsewhere is unknown because typically only symptomatic individuals are diagnosed. We performed a serological study of blood donors in Scotland in the spring of 2020 to detect neutralising antibodies to SARS-CoV-2 as a marker of past infection and epidemic progression.AimOur objective was to determine if sera from blood bank donors can be used to track the emergence and progression of the SARS-CoV-2 epidemic.MethodsA pseudotyped SARS-CoV-2 virus microneutralisation assay was used to detect neutralising antibodies to SARS-CoV-2. The study comprised samples from 3,500 blood donors collected in Scotland between 17 March and 18 May 2020. Controls were collected from 100 donors in Scotland during 2019.ResultsAll samples collected on 17 March 2020 (n = 500) were negative in the pseudotyped SARS-CoV-2 virus microneutralisation assay. Neutralising antibodies were detected in six of 500 donors from 23 to 26 March. The number of samples containing neutralising antibodies did not significantly rise after 5-6 April until the end of the study on 18 May. We found that infections were concentrated in certain postcodes, indicating that outbreaks of infection were extremely localised. In contrast, other areas remained comparatively untouched by the epidemic.ConclusionAlthough blood donors are not representative of the overall population, we demonstrated that serosurveys of blood banks can serve as a useful tool for tracking the emergence and progression of an epidemic such as the SARS-CoV-2 outbreak.
dc.format.mediumPrint
dc.languageeng
dc.publisherEuropean Centre for Disease Control and Prevention (ECDC)
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectISARIC4C Investigators
dc.subjectHumans
dc.subjectPneumonia, Viral
dc.subjectCoronavirus Infections
dc.subjectAntibodies, Viral
dc.subjectEnzyme-Linked Immunosorbent Assay
dc.subjectNeutralization Tests
dc.subjectPopulation Surveillance
dc.subjectPrevalence
dc.subjectCluster Analysis
dc.subjectSensitivity and Specificity
dc.subjectSeroepidemiologic Studies
dc.subjectInhibitory Concentration 50
dc.subjectModels, Immunological
dc.subjectAdult
dc.subjectBlood Donors
dc.subjectUrban Population
dc.subjectScotland
dc.subjectFemale
dc.subjectMale
dc.subjectAntibodies, Neutralizing
dc.subjectPandemics
dc.subjectGeography, Medical
dc.subjectBetacoronavirus
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.titleDetection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020.
dc.typeArticle
prism.issueIdentifier42
prism.publicationDate2020
prism.publicationNameEuro Surveill
prism.volume25
dc.identifier.doi10.17863/CAM.63484
dcterms.dateAccepted2020-08-11
rioxxterms.versionofrecord10.2807/1560-7917.ES.2020.25.42.2000685
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2020-10
dc.contributor.orcidKooblall, Kreepa [0000-0001-9547-2067]
dc.contributor.orcidLópez-Camacho, César [0000-0001-7932-2341]
dc.contributor.orcidSampson, Oliver [0000-0001-8727-0588]
dc.contributor.orcidScreaton, Gavin R [0000-0002-3549-4309]
dc.contributor.orcidTemperton, Nigel [0000-0002-7978-3815]
dc.identifier.eissn1560-7917
rioxxterms.typeJournal Article/Review
pubs.funder-project-idMRC (MR/P502091/1�)
pubs.funder-project-idMedical Research Council (G0701652)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International